• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Pharmacological treatment and current controversies in COPD.慢性阻塞性肺疾病（COPD）的药物治疗及当前争议
F1000Res. 2019 Aug 29;8. doi: 10.12688/f1000research.19811.1. eCollection 2019.
2
Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice.COPD 患者 GOLD A/B 初始吸入皮质类固醇使用的决定因素：英国普通实践的回顾性研究。
NPJ Prim Care Respir Med. 2017 Jun 29;27(1):43. doi: 10.1038/s41533-017-0040-z.
3
Overuse of long-acting β-agonist/inhaled corticosteroids in patients with chronic obstructive pulmonary disease: time to rethink prescribing patterns.慢性阻塞性肺疾病患者长效β受体激动剂/吸入性糖皮质激素的过度使用：是时候重新思考处方模式了。
Postgrad Med. 2023 Nov;135(8):784-802. doi: 10.1080/00325481.2023.2284650. Epub 2024 Jan 10.
4
Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD.联合使用吸入性皮质类固醇：噻托溴铵联合福莫特罗治疗 COPD 的两项 III 期研究的汇总数据。
NPJ Prim Care Respir Med. 2017 Feb 24;27(1):13. doi: 10.1038/s41533-016-0009-3.
5
What is in the guidelines about the pharmacological treatment of chronic obstructive pulmonary disease?这些指南中关于慢性阻塞性肺疾病的药物治疗有哪些内容？
Expert Rev Respir Med. 2013 Apr;7(2 Suppl):43-51. doi: 10.1586/ers.13.17.
6
Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.长效支气管扩张剂或吸入性皮质类固醇联合治疗的 COPD 患者对当前指南的依从性。
Int J Chron Obstruct Pulmon Dis. 2012;7:201-9. doi: 10.2147/COPD.S25805. Epub 2012 Mar 15.
7
Incidence, Predictors, and Clinical Implications of Discontinuing Therapy with Inhaled Long-Acting Bronchodilators among Patients with Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病患者停用吸入长效支气管扩张剂治疗的发生率、预测因素及临床意义
COPD. 2016 Oct;13(5):540-6. doi: 10.3109/15412555.2016.1141877. Epub 2016 Mar 2.
8
Current drug treatment, chronic and acute.目前的药物治疗，包括慢性和急性的。
Clin Chest Med. 2014 Mar;35(1):177-89. doi: 10.1016/j.ccm.2013.09.009.
9
Emerging trends in the therapy of COPD: bronchodilators as mono- and combination therapies.慢性阻塞性肺疾病治疗的新趋势：支气管扩张剂的单一疗法和联合疗法
Drug Discov Today. 2007 Jun;12(11-12):472-8. doi: 10.1016/j.drudis.2007.04.003. Epub 2007 Apr 26.
10
[Current position of new fixed-dose combination of tiotropium and olodaterol - its role in the treatment of chronic obstructive pulmonary disease in the Czech Republic].[噻托溴铵与奥达特罗新固定剂量复方制剂的当前地位——其在捷克共和国慢性阻塞性肺疾病治疗中的作用]
Vnitr Lek. 2016 Winter;62(12):1011-1020.

引用本文的文献

1
Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD.在 COPD 存在氧化应激的情况下使用硫醇及其对吸入皮质类固醇的影响。
Respir Res. 2023 Jul 31;24(1):194. doi: 10.1186/s12931-023-02500-8.
2
Matrix Metalloproteinases in Chronic Obstructive Pulmonary Disease.基质金属蛋白酶在慢性阻塞性肺疾病中的作用。
Int J Mol Sci. 2023 Feb 14;24(4):3786. doi: 10.3390/ijms24043786.
3
Extract Alleviates COPD by Inhibiting the Inflammatory Response via Downregulation of NF-κB.提取物通过下调 NF-κB 抑制炎症反应缓解 COPD。
Molecules. 2022 Nov 26;27(23):8243. doi: 10.3390/molecules27238243.
4
Analysis of the Clinical Efficacy and Molecular Mechanism of Xuefu Zhuyu Decoction in the Treatment of COPD Based on Meta-Analysis and Network Pharmacology.基于荟萃分析和网络药理学探讨血府逐瘀汤治疗 COPD 的临床疗效及分子机制
Comput Math Methods Med. 2022 Nov 26;2022:2615580. doi: 10.1155/2022/2615580. eCollection 2022.
5
Combined docking and machine learning identify key molecular determinants of ligand pharmacological activity on β2 adrenoceptor.联合对接和机器学习确定β2 肾上腺素能受体配体药理活性的关键分子决定因素。
Pharmacol Res Perspect. 2022 Oct;10(5):e00994. doi: 10.1002/prp2.994.
6
Comparing the Efficacy and Safety Profile of Triple Fixed-Dose Combinations in COPD: A Meta-Analysis and IBiS Score.比较慢性阻塞性肺疾病三联固定剂量组合的疗效和安全性：一项荟萃分析和IBiS评分
J Clin Med. 2022 Aug 1;11(15):4491. doi: 10.3390/jcm11154491.
7
Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone.COPD 患者起始使用含超细颗粒丙酸倍氯米松与细颗粒丙酸氟替卡松的固定剂量吸入治疗时肺炎风险的类间差异。
Int J Chron Obstruct Pulmon Dis. 2022 Feb 15;17:355-370. doi: 10.2147/COPD.S342357. eCollection 2022.
8
Beyond Dual Bronchodilation - Triple Therapy, When and Why.超越双支气管扩张 - 三联疗法，何时及为何。
Int J Chron Obstruct Pulmon Dis. 2022 Jan 14;17:165-180. doi: 10.2147/COPD.S345263. eCollection 2022.
9
Identification of Potential Key Genes in the Pathogenesis of Chronic Obstructive Pulmonary Disease Through Bioinformatics Analysis.通过生物信息学分析鉴定慢性阻塞性肺疾病发病机制中的潜在关键基因
Front Genet. 2021 Nov 3;12:754569. doi: 10.3389/fgene.2021.754569. eCollection 2021.
10
An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease.单克隆抗体治疗慢性阻塞性肺疾病的安全性与有效性概述
Biologics. 2021 Aug 27;15:363-374. doi: 10.2147/BTT.S295409. eCollection 2021.

本文引用的文献

1
Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics.基于巯基的药物在肺部医学中的应用：远不止于黏液溶解剂。
Trends Pharmacol Sci. 2019 Jul;40(7):452-463. doi: 10.1016/j.tips.2019.04.015. Epub 2019 May 27.
2
Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.黏液溶解/抗氧化剂在慢性阻塞性肺疾病中的疗效和安全性：厄多司坦、卡博司坦和乙酰半胱氨酸的比较分析。
Respir Res. 2019 May 27;20(1):104. doi: 10.1186/s12931-019-1078-y.
3
Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways.噻托溴铵与奥达特罗在人支气管和小气道相互作用的药理学特性。
Pulm Pharmacol Ther. 2019 Jun;56:39-50. doi: 10.1016/j.pupt.2019.03.004. Epub 2019 Mar 12.
4
Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report.可治疗特征：21 世纪慢性气道疾病管理的新模式：可治疗特征在澳大利亚国际研讨会报告
Eur Respir J. 2019 May 9;53(5). doi: 10.1183/13993003.02058-2018. Print 2019 May.
5
Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD.在 ICS/LABA 治疗中添加 LAMA：COPD 三联疗法的荟萃分析。
Chest. 2019 Apr;155(4):758-770. doi: 10.1016/j.chest.2018.12.016. Epub 2019 Jan 17.
6
Inhaled corticosteroids in COPD: the final verdict is….慢性阻塞性肺疾病中的吸入性糖皮质激素：最终结论是……
Eur Respir J. 2018 Dec 13;52(6). doi: 10.1183/13993003.01940-2018. Print 2018 Dec.
7
Triple therapy single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis.三联疗法与单双联长效支气管扩张剂治疗 COPD：系统评价和荟萃分析。
Eur Respir J. 2018 Dec 13;52(6). doi: 10.1183/13993003.01586-2018. Print 2018 Dec.
8
POINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? Yes.观点：长效抗胆碱能药物/长效β2受体激动剂联合治疗应作为慢性阻塞性肺疾病的初始维持治疗吗？应该。
Chest. 2018 Oct;154(4):746-748. doi: 10.1016/j.chest.2018.06.022.
9
Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.罗氟司特治疗慢性阻塞性肺疾病的抗炎作用（ROBERT）：一项为期 16 周、随机、安慰剂对照试验。
Lancet Respir Med. 2018 Nov;6(11):827-836. doi: 10.1016/S2213-2600(18)30331-X. Epub 2018 Sep 14.
10
Inhaled corticosteroid containing combinations and mortality in COPD.慢性阻塞性肺疾病中含吸入性皮质类固醇的联合用药与死亡率
Eur Respir J. 2018 Dec 13;52(6). doi: 10.1183/13993003.01230-2018. Print 2018 Dec.

慢性阻塞性肺疾病（COPD）的药物治疗及当前争议

Pharmacological treatment and current controversies in COPD.

作者信息

Cazzola Mario, Rogliani Paola, Stolz Daiana, Matera Maria Gabriella

机构信息

Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital of Basel, Basel, Switzerland.

出版信息

F1000Res. 2019 Aug 29;8. doi: 10.12688/f1000research.19811.1. eCollection 2019.

DOI:10.12688/f1000research.19811.1
PMID:31508197
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6719668/
Abstract

Bronchodilators, corticosteroids, and antibiotics are still key elements for treating chronic obstructive pulmonary disease in the 2019 Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations and this is due in part to our current inability to discover new drugs capable of decisively influencing the course of the disease. However, in recent years, information has been produced that, if used correctly, can allow us to improve the use of the available therapies.

摘要

支气管扩张剂、皮质类固醇和抗生素仍然是2019年慢性阻塞性肺疾病全球倡议（GOLD）推荐的治疗慢性阻塞性肺疾病的关键要素，部分原因在于我们目前无法发现能够决定性地影响该疾病进程的新药。然而，近年来已产生了一些信息，如果正确使用，这些信息能够让我们改进现有疗法的使用。